SMN dosage analysis and risk assessment for spinal muscular atrophy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

1. Assessment of Spinal Muscular Atrophy Carrier Status by DeterminingInternational journal of neonatal screening · 2020
   Article
2. Single-sperm analysis for recurrence risk assessment of spinal muscular atrophy.European journal of human genetics : EJHG · 2010
   Article
3. Carrier incidence for spinal muscular atrophy in southern Chinese.Journal of neurology · 2004
   Article

Corrections and comments

• Comment on
  Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling.1999
• Comment on
  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.2002

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as